Dan LeBatard offers the most intelligent and mature take on PEDs in sports I’ve seen in ages. He asks us to take a step back and ask ourselves why it is we are so hung up on a certain, narrow kind of performance enhancement in sports when we never question it — indeed, we openly praise it — when athletes do insane things to their bodies, all in the name of staying on the field? Often things that could cause massive harm.
Stuff like Ronnie Lott cutting his finger off. Lomas Brown playing with a catheter. Players having ligaments taken from cadavers and inserted into their own bodies. Drug therapies and medical procedures that are wholly unnecessary for a normal quality of life but are accepted in the name of athletic performance. We are totally fine with these. We are not totally fine with others:
We are OK with Kirk Gibson hitting one of the most famous home runs ever on one steroid (cortisone), but we slam the Hall of Fame door on the face of everybody else who might have used the anabolic kind. Granted, cortisone is not a banned performance enhancer, but it certainly enhanced Gibson’s performance, which wouldn’t have been possible without it. Lost in the shouting of “Cheater!” and “Fraud!” from a pill-popping America is how often athletes have to go through the pharmacy for the healing properties of hormones — not just to hit home runs but because what they do for a daily living really hurts.
It is not enough to draw some line and say “well, [drug/procedure X] is banned and [drug/procedure Y] is not banned.” It makes people who like to pour crap on banned PED users feel better, but it’s a most pedantic distinction. Why are some procedures and drugs banned and others not? Why do we allow some sorts of performance enhancement or enabling but not others? If it’s OK for Kirk Gibson to take a drug that allowed him to take the field when he otherwise could not have, why do we not allow other players to take other drugs that allow them to take the field when they otherwise can’t?
More broadly, as fans and observers, why do we seem to care so much and get so annoyed at certain sorts of seemingly unnatural acts undertaken by athletes but don’t care a bit — or, alternatively, fully expect — so many others?
Jon Morosi of FOX Sports reports that the Tigers are in discussions with free agent starter Jordan Zimmermann. His sources have told him that the talks have become “serious”.
Zimmermann, 29, has a career 3.32 ERA across parts of seven seasons in the majors. He finished fifth in National League Cy Young Award balloting in 2014, finishing with a 2.66 ERA and a 182/29 K/BB ratio over 199 2/3 innings.
Among starters who have amassed at least 1,000 innings since 2009, only Cliff Lee, Dan Haren, Madison Bumgarner, and Zack Greinke have compiled a better strikeout-to-walk ratio than Zimmermann’s 4.09. While he doesn’t have the star power of other free agents such as Greinke or David Price, the Tigers would certainly improve their rotation by bringing him on board.
Having already added Jesse Chavez and J.A. Happ to the mix and re-signing Marco Estrada early in the offseason, Blue Jays interim GM Tony LaCava said the team will continue to pursue pitching upgrades, as Sportsnet’s Ben Nicholson-Smith reports. Nicholson-Smith added that LaCava declined to comment on free agent ace David Price. It is believed that the Jays will not pursue Price and other big-name free agent starting pitchers given their November activity.
The Jays re-signed Estrada to a two-year, $26 million deal on November 13, acquired Chavez from the Athletics in exchange for reliever Liam Hendriks on November 20 and signed Happ to a three-year, $36 million deal on Friday.
Nicholson-Smith notes in a column on Sportsnet that the Jays need to address the bullpen in particular. That is especially true after swapping Hendriks, who had a career-best 2.92 ERA out of the Jays’ bullpen in 2015, for a back-end starting pitcher.
Jon Heyman of CBS Sports spoke to an anonymous baseball executive, who said that Nationals closer Jonathan Papelbon is “untradeable”. The Nationals are hoping to trade both Papelbon and the man he displaced, Drew Storen.
Papelbon has a poor reputation in baseball, particularly after a dugout altercation with superstar outfielder Bryce Harper. Focusing strictly on what he does on the field, Papelbon still gets the job done. The 35-year-old finished the last season with a combined 2.13 ERA, 24 saves, and a 56/12 K/BB ratio over 63 1/3 innings between the Phillies and Nationals.
The Nationals owe Papelbon $11 million for the 2016 season.
Baseball America’s J.J. Cooper reports that corner infielder Mike Hessman has retired from professional baseball after 20 seasons. Hessman hit 433 home runs in the minor leagues, an all-time record. He broke Buzz Arlett’s record this past August and with style as #433 was a grand slam.
Hessman, 37, was selected in the 16th round of the 1996 draft by the Braves and remained with the organization through the 2004 season. He then went to the Tigers from 2005-09, the Mets in 2010, then drifted into the Astros and Reds’ farm systems before returning to the Tigers for the last two years.
Hessman took 250 plate appearances at the major league level, batting .188/.272/.422 with 14 home runs and 33 RBI.